Navigation Links
Kinex Announces First Patient Dosed in Phase Ib Study of Oraxol, an Orally Dosed Paclitaxel
Date:10/28/2013

BUFFALO, N.Y., Oct. 28, 2013 /PRNewswire/ -- Kinex Pharmaceuticals today announced that the first patient has been dosed in its Phase Ib Oraxol study.  Oraxol allows for oral delivery of paclitaxel when combined with Hanmi Pharmaceutical's absorption enhancer, HM30181A.  This trial is being conducted in the United States.  Oraxol is in PII studies in Korea and will commence a PI in New Zealand in 2014.  Kinex has global development and commercialization rights for Oraxol, excluding Korea, Japan and India that are owned by Hanmi, and New Zealand and Australia which were recently licensed to Zenith Technology Corporation.

This single arm, dose escalation study is designed to bridge the safety, pharmacokinetics and tolerability of Oraxol that was observed by Hanmi Pharmaceutical in their Korean trials.  Kinex expects to enroll 25-35 patients.  Clinical studies of Oraxol to date suggest that this potent, oral version of paclitaxel will impact a broad spectrum of cancers.

Dr. Wen Wee Ma, MBBS, Assistant Professor at Roswell Park Cancer Institute and Primary Investigator for the Phase Ib trial stated, "Our team at Roswell Park has broad experience developing taxane based compounds.  Oraxol is an exciting program for us as it offers many important potential benefits to patients and clinicians including tolerability, convenience of oral administration and increased efficacy.  The design of this trial was guided by the predictive PK of Oraxol developed by Kinex and Roswell Park and we are extremely excited by its launch."

"The initiation of Kinex's Phase Ib is another important step in the Kinex /Hanmi collaboration," said Dr. Lyn Dyster, Senior Vice President of Operations. "The trial is des
'/>"/>

SOURCE Kinex Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Hanmi Pharmaceuticals to Assign the Rights to Five New Territories to Kinex as Part of the Orascovery Program Strategic Plan
2. Dr. David Hangauer, Chief Scientific Officer and Co-Founder, commits his career to Kinex Pharmaceuticals
3. Kinex Receives Research Support from the Hong Kong Innovation and Technology Commission (ITC)
4. Kinex Announces that the US FDA Allows their IND for Oraxol, an Oral Form of Paclitaxel that is in Phase II Clinical Trials in Korea, to Begin Clinical Trials in the US
5. Kinex Pharmaceuticals Will Take the Lead in the Orascovery Program Development in China
6. Kinex Announces that the US FDA Allows their IND to Begin KX02 Clinical Trials
7. Kinex Pharmaceuticals and Zenith Technology Corporation announce the execution of a collaborative licensing agreement
8. Kinex Pharmaceuticals Chief Scientific Officer, Dr. David Hangauer, named the American Cancer Societys 2013 Honoree for its Cuisine for a Cure event
9. Hanmi and Kinex Announced Korean FDA Allowance of the KX01 IND Application
10. Kinex Pharmaceuticals Appoints Mr. Patrick Gallagher Vice President of Business Development and Investor Relations
11. Kinex Pharmaceuticals Receives Substantial Strategic Investment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... LONDON , May 6, 2015 ... HIV maintenance therapy with dolutegravir and rilpivirine ... start of a Phase III clinical trial programme ... (Tivicay®) and rilpivirine (Edurant® [1] ) as maintenance ... III programme comprises two replicate studies evaluating 48 ...
(Date:5/6/2015)... , May 6, 2015   Wilson Therapeutics ... CEO Jonas Hansson has been invited to ... the annual BioEquity Conference, this year to be held ... May 19 th . About WTX101 ... is currently in Phase 2 testing for Wilson Disease. ...
(Date:5/6/2015)... , May 6, 2015 ... join the Wellcome Trust and the Bill & ... Kymab, a leading monoclonal antibody biopharmaceutical ... an additional US$50 million to complete a US$90 ... being invested by Woodford Patient Capital Trust plc ...
Breaking Medicine Technology:ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 2ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 3ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 4ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 5ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 6ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 7ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 8ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 9ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 10Wilson Therapeutics To Present As A "Next Wave" Company During BioEquity 2015 Conference In Vienna On May 19th 2Kymab Secures US$90 Million Funding 2Kymab Secures US$90 Million Funding 3Kymab Secures US$90 Million Funding 4
... 2011  Allocate Software plc, the leading provider of workforce ... its presence in the US with the announcement that ... scheduling solution, to create and manage schedules for its ... a leading provider of a diverse range of imaging ...
... Endo Pharmaceuticals (Nasdaq: ENDP ) today announced that ... present a corporate overview at the Bank of America Merrill ... at 7:30 a.m. ET.  The conference will be held at ... A live webcast and audio archive of the presentation will ...
Cached Medicine Technology:Allocate Software's Healthroster Selected by Austin Radiological Association 2
(Date:5/6/2015)... Launch Corporation, LLC. is pleased to announce that Launch Trampoline ... Tanguay Avenue. Owned and operated by Rick Arnold and Phil ... New England. , “We are extremely excited for Rick and ... and CEO of Launch. “They have established great roots in ... continue to establish that positive growth in the greater Nashua ...
(Date:5/6/2015)... May 06, 2015 The SGNY Group ... York City, announced today that it was named a ... a presentation video produced on behalf of Intarcia Therapeutics. ... category of motion graphics. , The competition sponsored by ... over 6000 entries from 22 countries. The competition ...
(Date:5/5/2015)... 06, 2015 It’s not your usual Veterans ... their classic cars and motorcycles to the 3rd Annual “Crusin ... 8 p.m. at the Lincoln VA Clinic, 600 S. 70th ... to check out each other’s rides, but also to talk ... and services. , Staff from the VA Nebraska-Western Iowa ...
(Date:5/5/2015)... Private equity consultant and international research ... that its dental stem cell biobank project, Provia ... April, 2015 –and posted yet another exciting record. This ... and represents a significant 54% increase over last April ... is conducted via the Store-A-Tooth brand. The company has ...
(Date:5/5/2015)... “Given that Hispanics are one in six people ... are a major step in the arsenal of facts documenting ... past 30 years, data have accumulated that the health of ... the urgency and the need to create new models of ... all,” said Jane L. Delgado, PhD, MS, President and CEO ...
Breaking Medicine News(10 mins):Health News:Jump Up and Celebrate: Launch Trampoline Park Opens in Nashua, NH 2Health News:The SGNY Group Wins Platinum Hermes Creative Award 2Health News:Grace Century’s Dental Stem Cell Biobank Project Announces Serial Record Enrollment Growth 2Health News:Grace Century’s Dental Stem Cell Biobank Project Announces Serial Record Enrollment Growth 3Health News:“Its about time,” Declares the National Alliance for Hispanic Health on First CDC Study of Hispanic Health 2
... the brain could play a key role in regulating ... plaques implicated in the development of Alzheimer,s disease, according ... A group led by Domenico Pratico, professor of pharmacology ... of the protein, called 12/15-Lipoxygenase, in the brain three ...
... News) -- Researchers who found the earliest known ... the evolution of complex reproductive behavior in early dinosaurs. ... million years older than previously known nesting sites. It ... Massospondylus , a relative of the giant, long-necked sauropods ...
... (HealthDay News) -- Researchers who identified a protein that ... eventually lead to new treatments for the neurodegenerative disease. ... in neurons in the striatum, the part of the ... Parkinson,s disease in mice, the researchers found that RGS4 ...
... a genetic outlier, which has prevented scientists from discovering the ... Health and Yale University School of Medicine have devised a ... , the major cause of human malaria. This new approach ... and opens the door to further genetic discovery for the ...
... Calif. (January 25, 2012) Gardasil, the human papillomavirus ... adolescents and young adults, does not trigger autoimmune conditions ... multiple sclerosis after vaccination in young women, according to ... Medicine . Kaiser Permanente researchers used electronic health ...
... , WEDNESDAY, Jan. 25 (HealthDay News) -- Learning to ... with autism make plans and complete complex daily tasks, ... that people with autism can live independent, flexible lives, ... Durham University in England. The researchers compared how ...
Cached Medicine News:Health News:Protein in the brain could be a key target in controlling Alzheimer's 2Health News:Oldest Known Dinosaur Nesting Site Found 2Health News:Protein That Controls Movement Does the Opposite in Parkinson's 2Health News:Researchers discover method to unravel malaria's genetic secrets 2Health News:Kaiser Permanente study finds Gardasil does not trigger autoimmune conditions after vaccination 2Health News:'Inner Dialogue' Might Aid People With Autism 2
... The AlphaPette Pipettor is the ... beyond. Offers accuracy, comfort, and reliability. ... digital volume readout sub-micrometer. Easy interchangeable ... or tiny hands. Adjustable rapid pipet ...
... Pipetman Ultra is a fully adjustable, air-displacement ... It is the latest member of the ... characteristics: robustness, accuracy, and precision. We also ... feedback from our customers. Eight models cover ...
... Thermo Labsystems was designed specifically to combine ... such as the new fast dial system ... help to define this as a new ... interchangeable handle plate offers a custom fit ...
... In the specialty areas ... or intensive care work, it ... in your practice. Alokas motorized ... Doppler and Tissue Harmonic Echo ...
Medicine Products: